Analyst: In Merck-Idenix deal, ‘biggest question’ is why Gilead wasn't the suitor
June 18, 2014 at 13:38 PM EDT
If Merck & Co.’s $4 billion bet on the hepatitis C drug being developed by Cambridge biotech firm Idenix Pharmaceuticals pays off, it will provide Merck with a slice of an estimated $50 billion market over the next decade...